Journey Medical (DERM) Insider Adam Buys 10,000 Shares

Smith Justin Adam, an insider at Journey Medical Corporation, bought 10,000 shares of the company on June 25, 2026. The transaction did not involve a pre-planned trading program, and the shares traded at $6.22 on the Nasdaq Capital Market.

Insider Buying and Selling at Journey Medical Corporation

On June 25, 2026, multiple insiders, including Smith Justin Adam, each purchased 10,000 shares of Journey Medical Corporation. These transactions were not part of a Rule 10b5-1 trading plan. Other insiders who made similar purchases on the same day include Michael Cooper Pearce, Neil Herskowitz, and Lindsay MD Rosenwald. Previously, on April 22, 2026, CFO Joseph Benesch and Chief Operating Officer Ramsey Alloush also acquired shares, buying 28,907 and 62,795 shares respectively.

Other Institutional Activity in Journey Medical Corporation

Institutional investors have been actively adjusting their holdings in Journey Medical Corporation. Wasatch Advisors LP significantly increased its stake by 817,095 shares to hold a total of 2,133,370 shares valued at approximately $10.0 million, marking a 62.1% increase. In contrast, Tang Capital Management LLC reduced its position by 244,596 shares, ending with 1,610,000 shares worth about $7.6 million, a 13.2% decrease. Vanguard Capital Management LLC opened a new position with 1,082,080 shares valued at $5.1 million. BlackRock, Inc. added 253,078 shares, reaching a total of 972,862 shares valued at $4.6 million, while Opaleye Management Inc. slightly reduced its holdings by 15,000 shares to 960,000 shares, valued at $4.5 million.

Journey Medical Corporation Stock Down 9.4%

Shares of NasdaqCM:DERM traded near $6.22 on Saturday. Journey Medical Corporation has a market capitalization of approximately $182.3 million. The company is not currently profitable, as indicated by its negative forward P/E ratio. The stock's beta is 1.097, suggesting moderate volatility. Over the past year, the stock has fluctuated between a low of $4.31 and a high of $9.56. The 50-day moving average is $5.79, while the 200-day moving average stands at $7.12.

Analysts Set New Price Targets

Analysts have expressed positive sentiments about Journey Medical Corporation. On March 26, 2026, HC Wainwright & Co. reiterated a 'buy' rating with a price target of $13.0. The consensus among analysts is a 'strong buy' with a mean price target of $13.5, based on opinions from four analysts.

About Journey Medical Corporation

Journey Medical Corporation is a pharmaceutical company based in Scottsdale, Arizona. It focuses on developing and marketing treatments for dermatological conditions in the U.S. The company's products include Qbrexza, Accutane, and Amzeeq, among others. Led by CEO Claude Maraoui, Journey Medical operates with a team of 58 employees.

Bottom Line

Insider activity at Journey Medical Corporation, including recent purchases by Smith Justin Adam and others, reflects ongoing interest in the company's prospects. Institutional investors have also made significant adjustments to their holdings. As always, remember that insider transactions are disclosed after the fact and may not indicate future stock performance.